(Reuters) – Bluebird bio Inc < BLUE.O> said on Monday it has set at $419,500 the wholesale list price of its newly approved multiple myeloma therapy developed with Bristol-Myers Squibb Co.
The U.S. FDA on Friday approved the treatment, Abecma, for adult patients with multiple myeloma after four or more prior lines of therapy.
Brokerage Piper Sandler expects the treatment to bring in sales of over $2.5 billion by 2030.
The list price is not necessarily what patients actually pay and “out-of-pocket” costs vary based on the duration of the treatment and individual healthcare plans.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila)
